Exosomal B7H3 drives immunosuppression and serves as a biomarker for PD-1 blockage response in head and neck squamous cell carcinoma.
Exosomal immune checkpoint markers in blood predict immunotherapy response in head-and-neck cancer, supporting personalized checkpoint inhibitor selection.
This Cancer Biology & Medicine study characterized exosomal B7H3, an immune checkpoint ligand shed from HNSCC cells, as both a driver of tumor immune evasion and a liquid biopsy-accessible biomarker for predicting checkpoint immunotherapy response. The work positions exosomal B7H3 measurement as a non-invasive companion diagnostic for anti-PD-1 therapy in HNSCC.
What the study was
- Study design
- translational_biomarker
- Population
- Head and neck squamous cell carcinoma patients
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Cancer Biol Med
Why it surfaced
Combines mechanistic insight (B7H3-mediated immunosuppression) with clinical utility (exosomal B7H3 as liquid biopsy predictor of anti-PD-1 response) in HNSCC; liquid biopsy angle intersects two active topics; preliminary translational evidence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.